Experiment 346851
Compounds isolated
Details
| Property | Value |
|---|---|
| Pharmacology | |
| Administration route | IV |
| Organism | Empty organism |
| Citation | VERWEIJ,J: WANDERS,J: GIL,T: SCHOFFSKI,P: CATIMEL,G: TE VELDE,A: DE MULDER,PHM:. (1996). PHASE II STUDY OF RHIZOXIN IN SQUAMOUS CELL HEAD AND NECK CANCER.. 73(3) |
| Amount utilized | |
| Compound isolated | |
| Disease | 32 PATIENTS WITH RECURRENT OR METASTATIC SQUAMOUS CELL HEAD AND NECK CANCER PARTICIPATED IN A PHASE II CLINICAL TRIAL TOXICITY MAINLY CONSISTED OF PAIN AT TUMOR SITE AND LEUCOCYTOPENIA. RHIZOXIN AT THIS DOSE AND SCHEDULE HAS MINOR ACTIVITY. IN RECURRENT AND/OR METASTATIC SQUAMOUS CELL HEAD AND NECK CANCER. |
| Dose amount | 2.0 MG |
| Number | 1 |
| Qualitative result | WEAK ACTIVITY |
| Animal | HUMAN ADULT |
| Per unit | SQ M |
| Dose expression | DOSE |